title: [Nivolumab, a new hope in non-small cell lung cancer].
abstract: Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of twoyears in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.
authors.affiliation: Gustave-Roussy Cancer Campus, département d'oncologie médicale, 94800 Villejuif, France.
authors.forename: Ronan
authors.initials: R
authors.lastname: Flippot
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Tenon, service de pneumologie, 75020 Paris, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Fallet
authors.affiliation: Gustave-Roussy Cancer Campus, département d'oncologie médicale, 94800 Villejuif, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.affiliation: Gustave-Roussy Cancer Campus, département d'oncologie médicale, 94800 Villejuif, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.affiliation: Assistance publique-Hôpitaux de Paris, hôpital Tenon, service de pneumologie, 75020 Paris, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.affiliation: Hôpital Louis-Pasteur, service d'oncologie et hématologie, 28630 Chartres-Le-Coudray, France. Electronic address: svignot@ch-chartres.fr.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008175:Lung Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D018579:Patient Selection
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab
keywords: Cancer bronchique non à petites cellules; Immunotherapy; Immunothérapie; Nivolumab; Non-small cell lung cancer